Actively Recruiting
Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia
Led by Novartis Pharmaceuticals · Updated on 2026-05-04
326
Participants Needed
1
Research Sites
131 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is an open label, randomized, prospective, type I hybrid effectiveness- implementation, pragmatic clinical trial to evaluate the impact of a targeted lipid optimization program on LDL-C control in participants with dyslipidemia who are at high risk or very high risk of cardiovascular events.
CONDITIONS
Official Title
Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of atherosclerotic cardiovascular disease (coronary heart disease, peripheral arterial disease, and/or cerebrovascular disease)
- High risk or very high risk for cardiovascular events according to 2019 ESC/EAS guidelines for dyslipidemia management
- Lipid levels meeting high risk (LDL-C 60 mg/dl or non-HDL-C 100 mg/dl) or very high risk (LDL-C 55 mg/dl or non-HDL-C 85 mg/dl) criteria
- Male or female participants aged 18 years or older
- Seen by a specialist prescribing advanced lipid-lowering treatments (cardiologist, endocrinologist, or relevant specialist)
- Currently taking maximum-tolerated statins
- Able to participate in an educational program including watching online videos
- Capable of giving signed informed consent and complying with study requirements
You will not qualify if you...
- Any surgical or medical condition that may increase risk or prevent compliance as judged by the investigator
- Unwillingness or inability (physical or cognitive) to follow study procedures and visits
- Participation in any other interventional study
- Inability to travel to study sites for in-person clinic visits
- Responsible physician decides not to engage the patient
- Refusal to sign consent and participate in the study
- Other protocol-defined criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Novartis Investigative Site
Abu Dhabi, United Arab Emirates
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here